Cargando…
CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
The prognostic impact of immunophenotypic CD34(+)CD38(−)CD123(+) leukemic stem cell (iLSC) frequency at diagnosis has been demonstrated in younger patients treated by intensive chemotherapy, however, this is less clear in older patients. Furthermore, the impact of iLSC in patients treated by hypomet...
Autores principales: | Vergez, François, Nicolau-Travers, Marie-Laure, Bertoli, Sarah, Rieu, Jean-Baptiste, Tavitian, Suzanne, Bories, Pierre, Luquet, Isabelle, De Mas, Véronique, Largeaud, Laetitia, Sarry, Audrey, Huguet, Françoise, Delabesse, Eric, Bérard, Emilie, Récher, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281486/ https://www.ncbi.nlm.nih.gov/pubmed/32384744 http://dx.doi.org/10.3390/cancers12051174 |
Ejemplares similares
-
Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023) -
Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022) -
Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019) -
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022) -
Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)